Superluminal Medicines Funding: $158M Raised, Series A
Superluminal Medicines is based in Boston. It has raised $158M in total funding. Latest round: Series A.
Superluminal Medicines funding overview
Superluminal Medicines is based in Boston. Superluminal Medicines has raised $158M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in September 2024. The round record for Superluminal Medicines runs through 2024; nothing later has been disclosed. Investors on record include RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, Gaingels, Catalio Capital Management and 1 others. 7 distinct backers are named across the disclosed rounds.
Superluminal Medicines at a glance
Total raised
$158M
Latest round
Series A
Latest round date
September 2024
Headquarters
Boston
Notable investors
RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, Gaingels, Catalio Capital Management, Cooley LLP
Frequently asked about Superluminal Medicines funding
How much has Superluminal Medicines raised?
Superluminal Medicines has raised $158M in total disclosed funding across the rounds on record.
Who has invested in Superluminal Medicines?
RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, Gaingels, Catalio Capital Management are named among the investors backing Superluminal Medicines.
What was the latest Superluminal Medicines funding round?
The most recent disclosed round is a Series A, announced in September 2024.
Where is Superluminal Medicines based?
Superluminal Medicines is based in Boston.
When did Superluminal Medicines last raise?
The last disclosed Superluminal Medicines round closed in September 2024 at Series A.
Superluminal Medicines totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Boston below to benchmark round size and investor mix.
